Researchers have identified a biological mechanism that helps explain why some lung and ovarian cancers become resistant to ...

A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free ...

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...

A lung cancer trial bolsters a long-held idea that treatment timing matters, showing a simple shift could help immunotherapy ...

Based on breakthrough findings from Dr. Adams' lab uncovering a novel druggable cellular detoxification pathway driving Cisplatin resistance in NSCLC, this collaboration aims to design novel ...

Adding nivolumab to neoadjuvant chemotherapy significantly improved 5-year overall survival among patients with resectable non-small cell lung cancer (NSCLC), according to findings from a phase 3 ...

Drugmakers have poured billions of dollars into developing ADCs. The medicines are designed to deliver potent chemotherapy directly to cancer cells while sparing surrounding healthy cells. That's ...

Laura Hamann's story is part of a growing trend that's changing everything you thought you knew about lung cancer.

Chemotherapy has long been a cornerstone of cancer treatment, saving millions of lives. Drugmakers have poured billions of dollars into developing ADCs. The medicines are designed to deliver potent ...